


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-64. Canceled

65. (Previously Presented) A compound of formula I,



wherein:

R^1 represents Het¹, $\text{R}^{1a}\text{C(O)-}$ or $\text{D-A-N(H)-[Q]}_n\text{-C(O)-E-C(O)-}$;

R^{1a} represents:

H,

aryl optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $\text{N}(\text{R}^{3a})\text{R}^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy,

aromatic or part-aromatic C_{13-14} tricyclic carbocyclyl optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $\text{N}(\text{R}^{3a})\text{R}^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy, and when the C_{13-14} tricyclic carbocyclyl is part-aromatic, a non-aromatic part of the C_{13-14} tricyclic carbocyclyl is optionally substituted by one or two oxo groups or

C_{1-12} alkyl optionally substituted and/or terminated by one or more substituents selected from the group consisting of halo and aryl, wherein the aryl is optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $\text{N}(\text{R}^{3a})\text{R}^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy;

A represents C_{2-6} alkylene or $\text{A}^1\text{-C(O)N(H)-A}^2$, wherein A^2 is attached to D;

A¹ represents C₁₋₄ alkylene;

A² represents C₂₋₅ alkylene;


D represents -N(R^{2a})R^{2b}, -C(=NR^{2c})N(R^{2d})R^{2e} or -
N(R^{2f})C(=NR^{2g})N(H)R^{2h};

R^{2a} and R^{2b} independently represent H, C₁₋₆ alkyl, or Het², or
R^{2a} and R^{2b} together represent (CH₂)₃₋₆, wherein the (CH₂)₃₋₆ is
optionally interrupted by NR⁴ and/or is optionally substituted by
one or more C₁₋₄ alkyl groups;

R⁴ represents H, C₁₋₆ alkyl or Het³;

R^{2c} to R^{2h} independently represent H or C₁₋₆ alkyl;

E represents -E¹-Het⁴-, E^{2a}, -(CH₂)₀₋₃N(H)C(O)-E^{2b}-
C(O)N(H)(CH₂)₀₋₃- or is represented by the formula



E³ represents (CH₂)₁₋₂, CH=CH, CH=N, CH₂-N(R^a), (CH₂)₀₋₁C(O),
(CH₂)₀₋₁O or (CH₂)₀₋₁S;

R^a represents H or C₁₋₆ alkyl;

E¹ represents (CH₂)₀₋₂ or CH=CH;

E^{2a} and E^{2b} independently represent C₂₋₄ alkenylene, C₃₋₆
cycloalkylene, phenylene or naphthylene;







Het¹ to Het⁴ independently represent four- to twelve-
membered heterocyclic groups containing one or more heteroatoms
selected from N, O and S, which heterocyclic groups are
optionally substituted by one or more substituents selected from
the group consisting of =O, OH, halo, cyano, nitro, N(R^{3a})R^{3b}, C₁₋₄
alkyl and C₁₋₄ alkoxy;

R^{3a} and R^{3b} independently represent H or C₁₋₄ alkyl, or R^{3a}
represents -C(O)R⁵;

R⁵ represents H or C₁₋₄ alkyl;

Application No. 10/500,093
Amendment Dated 11/2/2009
Reply to Final Rejection of 9/2/2009

n represents 2, 3, 4 or 5;
each individual Q independently represents a structure
represented by formula Ia, Ib, Ic, Id, Ie or If



wherein

R⁶ represents H or C₁₋₆ alkyl;

R⁷ represents C₁₋₁₂ alkyl;

R⁸, R⁹, R¹⁰ and R¹¹ independently represent H or C₁₋₁₂ alkyl;

G represents CH or N;

L represents O or S; and

p, q and r independently represent 0, 1, 2 or 3;

provided that the compound comprises at least one structure represented by formula Ib, Ic, Id, Ie or If in which R⁶ or R⁷, R⁸, R⁹, R¹⁰ or R¹¹, respectively, represents branched, cyclic or part cyclic C₃₋₅ alkyl; or a pharmaceutically acceptable derivative thereof.

66. (Previously Presented) A compound as claimed in Claim 65, wherein:

R^{1a} represents H or C₁₋₁₂ alkyl optionally substituted and/or terminated by one or more substituents selected from halo and aryl optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, N(R^{3a})R^{3b}, C₁₋₄ alkyl and C₁₋₄ alkoxy; and

the compound comprises at least one structure represented by formula Ib, Ic, Id, Ie or If in which R⁷, R⁸, R⁹, R¹⁰ or R¹¹, respectively, represents branched, cyclic or part cyclic C₃₋₅ alkyl.

67. (Previously Presented) A compound as claimed in Claim 65, wherein aryl is phenyl or naphthyl.


68. (Previously Presented) A compound as claimed in Claim 65, wherein alkyl and alkoxy groups are:

- (a) straight-chain;
- (b) branched-chain and/or cyclic; or
- (c) part cyclic/acyclic.

69. (Previously Presented) A compound as claimed in Claim 65, wherein alkyl and alkoxy groups are:

- (a) saturated or unsaturated;
- (b) interrupted by one or more oxygen and/or sulfur atoms; and/or
- (c) unless otherwise specified, substituted by one or more halo atoms.

70. (Previously Presented) A compound as claimed in Claim 65, which is a compound of formula II,



wherein

R^1 represents Het¹, $\text{R}^{1a}\text{C}(\text{O})-$ or $\text{D}-\text{A}-\text{N}(\text{H})-\text{Q}^3-\text{Q}^2-\text{Q}^1-\text{C}(\text{O})-\text{E}-\text{C}(\text{O})-$;

Q^1 is absent or represents a structure represented by formula Ia, Ib, Ic, Id, Ie or If;

Q^2 represents a structure represented by formula Ib, Id, Ie or If; and

Q^3 represents a structure represented by formula Ib, Id, Ie or If, provided that:

(a) at least one of Q^1 , Q^2 and Q^3 represents a structure represented by formula Id, Ie or If; and

(b) at least one of R^6 or R^7 , R^8 , R^9 , R^{10} and R^{11} represents branched, cyclic or part cyclic C₃₋₅ alkyl, or a pharmaceutically acceptable derivative thereof.

71. (Previously Presented) A compound as claimed in Claim 65, wherein the compound comprises:

(a) at least one structure represented by formula Ib in which G represents N and R^6 represents branched, cyclic or part cyclic C₃₋₅ alkyl;


(b) at least one structure represented by formula Id in which p represents 0 and R^9 represents branched, cyclic or part cyclic C₃₋₅ alkyl; and/or

(c) at least one structure represented by formula Ie in which q represents 0 and R^{10} represents branched, cyclic or part cyclic C₃₋₅ alkyl.

72. (Previously Presented) A compound as claimed in Claim 65, wherein each of the at least one branched, cyclic or part cyclic C₃₋₅ alkyl groups independently represents isopropyl, cyclopropylmethyl, isopentyl or cyclopentyl.


73. (Previously Presented) A compound as claimed in Claim 65, wherein the compound comprises at least one structure represented by formula Ib, Ic, Id, Ie or If in which R^7 , R^8 , R^9 , R^{10} or R^{11} , respectively, represents isopropyl.

74. (Previously Presented) A compound as claimed in Claim 65, which compound comprises at least one structure represented by the formula



75-94. (Cancelled)

95. (Previously Presented) A compound of formula IIIa,



wherein

B^1 represents

a nine-membered aromatic heterocycle containing two heteroatoms selected from N, O and S.

$$B^{1a}C(\Omega) = \sigma$$

$$D = A = N(H) = \Omega^3 = \Omega^2 = \Omega^1 = C(\Omega) = E = C(\Omega) = \dots$$

R^{1a} represents

H,

phenyl optionally substituted by C₁₋₂ alkoxy,
9,10-dioxo-9,10-dihydroanthracenyl optionally
substituted by C₁₋₂ alkoxy,
saturated, optionally branched C₁₋₆ alkyl or
saturated C₁₋₃ n-alkyl, terminated by phenyl optionally
substituted by C₁₋₂ alkoxy;

A represents saturated C₂₋₄ alkylene or (CH₂)₁₋₃-C(O)N(H)-
(CH₂)₂₋₄;

D represents -N(R^{2a})R^{2b};

R^{2a} and R^{2b} independently represent

C₁₋₃ alkyl or a nine- or ten-membered aromatic
heterocycle containing one to three heteroatoms selected from N,
O and S, or

R^{2a} and R^{2b} together represent (CH₂)₃₋₅ optionally
interrupted by NR⁴;

R⁴ represents

C₁₋₃ alkyl or a nine- or ten-membered aromatic
heterocycle containing one to three heteroatoms selected from N,
O and S;

E represents

-(2,5-indolyl-,

-(CH₂)₀₋₂-(2,6-indolyl)-,

-CH=CH-(2,6-indolyl)-,


trans-ethenylene,

trans-cyclopropylene,

1,3- or 1,4-phenylene,

-CH₂N(H)C(O)-(1,3- or 1,4-phenylene)-C(O)N(H)CH₂- ,

or one of the following structures




Q^1 is absent or represents a structure represented by formula Ia, Ib, Ic, Id, Ie or If;


Q^2 represents a structure represented by formula Ib, Ie or If;

Q^3 represents a structure represented by formula Ib, Id, Ie or If;


wherein the structures of formulae Ia, Ib, Ic, Id, Ie and If are as follows




Ia





Ib



Ic



Id



wherein

R⁶ represents H or, when G represents N, R⁶ represents H or branched, cyclic or part cyclic C₃₋₅ alkyl;


R⁷, R⁸, R⁹, R¹⁰ and R¹¹ independently represent saturated, optionally branched C₁₋₆ alkyl or R⁸ represents H;

provided that the compound comprises at least one structure represented by formula Ie in which R¹⁰ represents branched, cyclic or part cyclic C₃₋₅ alkyl.

96. (Previously Presented) A compound as claimed in Claim 95 wherein the compound comprises at least one structure represented by formula Ie in which R¹⁰ represents cyclopropylmethyl, isopentyl, cyclopentyl or isopropyl.

97. (Previously Presented) A compound as claimed in Claim 95 wherein the compound comprises at least one structure represented by formula Ie in which R¹⁰ represents isopropyl.

98. (Previously Presented) A compound of formula IIb,



wherein

R¹ represents

a nine-membered aromatic heterocycle containing two heteroatoms selected from N, O and S,

HC(O)-,

(methoxyphenyl)C(O)-,

(9,10-dioxo-9,10-dihydroanthracenyl)C(O)-,

(saturated C₁₋₃ alkyl) C(O)-,

(methoxyphenylacetyl)C(O)-, or

(CH₃)₂N-A-N(H)-Q³-Q²-Q¹-C(O)-E-C(O)-;

A represents saturated C₂₋₄ n-alkylene or (CH₂)₂-C(O)N(H)-(CH₂)₃;



E represents -CH₂N(H)C(O)-(1,3-phenylene)-C(O)N(H)CH₂-;

Q¹ is absent or represents a structure represented by formula Ia, Ib, Ic, Id, Ie or If;


Q² represents a structure represented by formula Ib, Ie or If;

Q³ represents a structure represented by formula Ib, Id, Ie or If;


wherein the structures of formulae Ia, Ib, Ic, Id, Ie and If are as follows





Ia



Ic



Id



wherein

R⁶ represents H or, when G represents N, R⁶ represents H or branched, cyclic or part cyclic C₃₋₅ alkyl;

R⁷, R⁹, R¹⁰ and R¹¹ independently represent saturated, optionally branched C₁₋₃ alkyl;

provided that the compound comprises at least one structure represented by formula Ie in which R¹⁰ represents branched, cyclic or part cyclic C₃₋₅ alkyl.

99. (Previously Presented) A compound as claimed in Claim 98, wherein the compound comprises at least one structure represented by formula Ie in which R¹⁰ represents cyclopropylmethyl, isopentyl, cyclopentyl or isopropyl.

100. (Previously Presented) A compound as claimed in Claim 98, wherein the compound comprises at least one structure represented by formula Ie in which R¹⁰ represents isopropyl.

101. (Previously Presented) A compound as claimed in Claim 65, which compound is selected from the following:

(i) N-[5-({[5-({{3-(Dimethylamino)propyl}amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-[(3,3-dimethylbutanoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide;

(ii) N-[5-({[5-({{3-(Dimethylamino)propyl}amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide;

- (iii) *N*-[3-(Dimethylamino)propyl]-2-({{4-({{4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;
- (iv) *N*-[5-({{3-(Dimethylamino)propyl}amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-({{4-(formylamino)-1-isopropyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-1-isopropyl-1*H*-pyrrole-2-carboxamide
- (v) *N*-[5-({{5-({{3-(Dimethylamino)propyl}amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl}amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(formyl-amino)-1-isopentyl-1*H*-pyrrole-2-carboxamide;
- (vi) *N*-[5-({{5-({{3-(Dimethylamino)propyl}amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl}amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-(formyl-amino)-1-isopropyl-1*H*-pyrrole-2-carboxamide;
- (vii) *N*-[5-({{3-(Dimethylamino)propyl}amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-2-({{4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;
- (viii) 4-({{4-(Formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-1-iso-propyl-*N*-[1-methyl-5-({{3-(4-morpholinyl)propyl}amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-pyrrole-2-carboxamide;
- (ix) 4-(Formylamino)-*N*-[1-isopropyl-5-({{1-methyl-5-({{3-(1-pyrrolidinyl)-propyl}amino}carbonyl)-1*H*-pyrrol-3-yl}amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;
- (x) *N*-[5-({{5-({{3-(Dimethylamino)propyl}amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl}amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;
- (xi) 2-(Acetylamino)-*N*-[5-({{5-({{3-(dimethylamino)propyl}amino}carbonyl)-1-methyl-1*H*-pyrrol-3-

yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xii) 2-(Acetylamino)-*N*-(5-({[4-({[3-(dimethylamino)propyl]amino}-carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xiii) 2-(Acetylamino)-*N*-(5-{[(3-([3-(dimethylamino)propyl]amino)-3-oxo-propyl)amino}carbonyl]-1-methyl-1*H*-pyrrol-3-yl)-5-isopropyl-1,3-thiazole-4-carboxamide;

(xiv) *N¹,N³*-Bis(2-[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-amino)-2-oxoethyl)isophthalamide;

(xv) *N*-(5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-(acetylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xvi) *N*-(5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(acetyl-amino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xvii) *N²,N⁶*-Bis[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xviii) *N²,N⁶*-Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]-amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xix) *N²,N⁶*-Bis[5-({[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

- (xx) *N²,N⁵-Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)-propyl]amino}carbonyl)-1H-pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide;*
- (xxi) *2-({[4-({[4-(Acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl}-amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-N-[3-(dimethylamino)-propyl]-5-isopropyl-1,3-thiazole-4-carboxamide;*
- (xxii) *4-(Acetylamino)-N-[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl) propyl]amino}carbonyl)-1H-pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide;*
- (xxiii) *N-[1-Isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)-propyl]amino}carbonyl)-1H-pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide;*
- (xxiv) *N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-({[5-(formylamino)-2-methyl-3-thienyl]carbonyl}amino)-1-isopentyl-1H-pyrrole-2-carboxamide;*
- (xxv) *N-[5-({[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-2-[(3-methoxybenzoyl)amino]-1,3-thiazole-4-carboxamide;*
- (xxvi) *N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-{[{5-[(9,10-dioxo-9,10-dihydro-2-anthracenyl)carbonyl}-amino]-2-methyl-3-thienyl]carbonyl}amino]-1-isopentyl-1H-pyrrole-2-carboxamide;*
- (xxvii) *N-[1-(Cyclopropylmethyl)-5-({[5-({[3-(dimethylamino)propyl]-amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide;*

(xxviii) 1-Cyclopentyl-N-[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]-carbonyl}-amino)-1*H*-pyrrole-2-carboxamide;

(xxix) *N²,N⁷-Bis*[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide;

(xxx) 4-(Formylamino)-N-[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxi) 4-(Acetylamino)-N-[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxii) 4-(Formylamino)-N-[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxiii) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1*H*-pyrrole-2-carboxamide; and

(xxxiv) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-[(4-methoxyphenyl)acetyl] amino]-1-methyl-1*H*-pyrrole-2-carboxamide.

102. (Previously Presented) A compound as claimed in Claim 101 which is:

- (a) N -[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide;
- (b) N -[3-(Dimethylamino)propyl]-2-({[4-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;
- (c) N -[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-2-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;
- (d) N -[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide;
- (e) N^2,N^5 -Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]-amino}carbonyl)-1H-pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide;
- (f) N -[1-(Cyclopropylmethyl)-5-({[5-({[3-(dimethylamino)propyl]-amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide; or
- (g) N^2,N^7 -Bis[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthredicarboxamide.

103. (Previously Presented) A compound as claimed in Claim 95 which is N -[3-(dimethylamino)-propyl]-2-({[4-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

104. (Previously Presented) A compound as claimed in Claim 65, which binds to and/or has specificity for DNA sequences that contain at least one GC base pairing.

105. (Previously Presented) A compound as claimed in Claim 95 or 98, which binds to and/or has specificity for DNA sequences that contain at least one GC base pairing, provided that the compound comprises at least one structure represented by formula I_d, I_e or I_f.

106. (Previously Presented) A compound as claimed in Claim 65 which has different binding affinities at different minor groove binding sites in double-stranded DNA molecules having more than one minor groove binding site.

107. (Previously Presented) A compound as claimed in Claim 106, wherein the different minor groove binding sites comprise solely AT base pairs.

108. (Previously Presented) A pharmaceutical formulation including a compound as defined in Claim 65 in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.


Claims 109-118 (Canceled).

119. (Previously Presented) A method of stabilising a DNA duplex formed between first and second single strands of DNA, which method comprises contacting that DNA duplex with a compound as defined in Claim 65.


120. (Previously Presented) A method of enhancing the difference in melting temperatures between first and second DNA duplexes, wherein each DNA duplex is formed from a first single strand of DNA that is the same in each duplex and a second single strand of DNA that is different in each duplex, which method comprises contacting each DNA duplex with a compound as defined in Claim 65.

121. (Previously Presented) A process for the preparation of compounds of formula I as defined in Claim 65 which comprises:

(a) reaction of a compound of formula III,



wherein A^{a} represents A or, when a represents 0, then A^{a} represents A or A^2 , a is as defined below, with a compound of formula IV,




wherein A^{b} represents a direct bond or $-\text{A}^1\text{---C(O)}-$, L^1 represents a leaving group, a and b both represent integers from 0 to 5, the sum of a and b being 2, 3, 4 or 5;

(b) for compounds of formula I in which R^1 represents $\text{D}\text{---A}\text{---N(H)}\text{---[Q]}_n\text{---C(O)}\text{---E}\text{---C(O)}\text{---}$, reaction of two equivalents of a compound of formula V,



with a compound of formula VI,



wherein L^2 represents a leaving group, the two L^2 groups being the same or different; or

(c) deprotection of a protected derivative of a compound of formula I.

122. (Previously Presented) A compound of formula V, as defined in Claim 121, or a protected derivative thereof.